Blood
Articles in this Issue
HSCs with the “SUPER” power to make blood forever
Magrolimab and the tale of indigestible AML
Two clones, one niche: how CH shapes the MM microenvironment
Heterogeneity of high-potency multilineage hematopoietic stem cells and identification of “Super” transplantability
Abstract Hematopoietic stem cells (HSCs) are heterogeneous, and the quality of HSCs—that is, transplantability—is a key determinant for posttransplant hematopoietic reconstitution. H...
Clonal hematopoiesis is clonally unrelated to multiple myeloma and is associated with specific microenvironmental changes
Abstract Multiple myeloma (MM) initiation is dictated by genomic events. However, its progression from asymptomatic stages to an aggressive disease that ultimately fails to respond t...
A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up
Abstract FCARH143, an autologous B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor (CAR) T-cell (CAR-T) therapy, which incorporates a fully human BCMA-specific sing...
High incidence of severe TA-TMA increases mortality in adult allogeneic transplant recipients: a prospective MIDAS Consortium study
Abstract No prospective study has evaluated the incidence of transplant-associated thrombotic microangiopathy (TA-TMA) in adult allogeneic hematopoietic cell transplant (HCT) recipie...
Take five: the story of factor V regulation
Time-tested safety: FCARH143’s 5-year myeloma journey
Immunoglobulin-containing vacuoles in CLL
Magrolimab plus azacitidine vs physician’s choice for untreated <i>TP53</i>-mutated acute myeloid leukemia: the ENHANCE-2 study
Abstract Patients with TP53-mutated acute myeloid leukemia (AML) have an extremely poor prognosis, necessitating new treatments. The global, randomized, phase 3 ENHANCE-2 trial evalu...
A multiomics approach reveals novel regulators of plasma factor V levels, highlighting CLEC4M as a clearance receptor
Abstract Coagulation factor V (FV) is a key protein in maintaining the hemostatic balance, with abnormal plasma levels associated with both thrombotic and hemorrhagic conditions. We...
Modeling the HLH immune synapse uncovers critical roles for IS termination, cytokine intensity, and target cell death
Abstract Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening systemic hyperinflammatory syndrome arising in many contexts. Its underlying mechanisms are often unclear, but...
MIDAS touch on TA-TMA: golden gains through active screening
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy
Abstract Patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy (IC) have limited treatment options. The phase 3 ENHANCE-3 study aimed to determine whether...
Targeting JAK-STAT in macrophage activation syndrome—no MAS!
NGS-based IG/TR gene rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation
Abstract We comprehensively profiled the landscape of immunoglobulin (IG) and T-cell receptor (TR) rearrangements at diagnosis in 1212 patients with acute lymphoblastic leukemia (ALL...
HLH: it is all about communication
Ruxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndrome
Abstract Macrophage activation syndrome (MAS) is believed to be caused by inappropriate proliferation and activation of the mononuclear phagocytic system. Adult-onset Still disease (...